Descriptive Analysis of Pediatric Studies Included in the European Union Post-Authorization Study Register from 2010...

Area of Science:

• Pharmacovigilance
• Pediatric Drug Safety
• Regulatory Science

Background:

• Post-Authorization Studies (PASs) are crucial for evaluating drug safety and efficacy after market approval.
• Pediatric populations often have unique responses to medications, necessitating specific safety monitoring.
• The European Union electronic Register of Post-Authorization Studies (EU PAS Register) is a key resource for tracking these studies.

Purpose of the Study:

• To analyze trends in pediatric PASs registered in the EU from 2010 to 2023.
• To identify patterns in study timing, age groups, and therapeutic areas.
• To examine funding sources and discuss pediatric-specific research considerations.

Main Methods:

• Screening of the EU PAS Register for studies exclusively on pediatric populations.
• Standardized data collection and descriptive analysis using univariate and multivariate linear regression.
• Assessment of trends over time and exploration of study characteristics.

Main Results:

• 165 pediatric PASs were analyzed, with a significant increase in annual numbers from 2010-2023.
• The majority were observational (86%) and used secondary data (53%).
• Pharmaceutical companies funded most studies (62%), with top therapeutic areas including anti-infectives, nervous system, and antineoplastic agents.

Conclusions:

• Post-marketing observational research in children has grown significantly.
• There is a need to encourage industry-academia collaboration in pediatric drug safety research.
• Regulatory guidance is essential to prioritize research in areas with unmet therapeutic needs for children.